Epsilogen and Lonza have successfully completed large-scale GMP manufacturing of MOv18 IgE, to treat platinum-resistant ovarian cancer (PROC) patients.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.